Educational Programs
The pharmaceutical industry's processes for drug development and manufacturing are in a time of extraordinary transition, characterized by new drug leads, new markets, new models, new instrumentation, new processes, and increasing regulatory constraints. There is an expanding and critical need to keep pace and to generate new knowledge, which will improve efficiencies in these areas. Furthermore, the supply of new personnel educated in Pharmaceutical Technology is expected to, at best, remain steady. Purdue University sees this situation as an opportunity for growth in the areas of our existing core competencies and beyond. We would like to expand research and education in manufacturing science, advanced manufacturing, Process Analytical Technology (PAT), sensor-based analysis, modeling, informatics, biomaterials, formulation design, Good Manufacturing Practices (GMP), and regulatory affairs.

In addition, the manufacture of orphan and legacy drugs is a problem for many pharmaceutical companies. The market for any single orphan drug is not big enough to be profitable for companies like Eli Lilly. Thus, there is a gap between the worldwide demand and supply of these critical drugs. The gap in providing these medicines has left many patients, both foreign and domestic, struggling to obtain an important element of their healthcare. It would thus make sense if reliable partners who are not involved in drug discovery could share or take over the responsibility of continuing with manufacturing these orphan drugs. However, developing reliable & cost-effective processes to manufacture these orphan drugs is not enough. There is a need to train the pharmaceutical professionals in developing countries like India, China and Russia in GMP regulations and practices to manufacture these drugs. Only then can we be assured that these countries will safely manufacture these orphan drugs for patients in their countries

Back to Education